

Review Form 1.7

Journal Name:	Asian Journal of Research and Reports in Neurology
Manuscript Number:	Ms_AJORRIN_113924
Title of the Manuscript:	GLP-1 AGONIST IN THE TREATMENT OF PARKINSON, NEW INNOVATIONS: A LITERATURE REVIEW
Type of the Article	

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><u>Compulsory</u> REVISION comments</p> <ol style="list-style-type: none"> 1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript) 2. Is the title of the article suitable? (If not please suggest an alternative title) 3. Is the abstract of the article comprehensive? 4. Are subsections and structure of the manuscript appropriate? 5. Do you think the manuscript is scientifically correct? 6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>		
<p><u>Minor</u> REVISION comments</p> <ol style="list-style-type: none"> 1. Is language/English quality of the article suitable for scholarly communications? 	<p>No comments are needed on the English language description.</p>	
<p><u>Optional/General</u> comments</p>	<p>Your review of the efficacy of GLP-1 receptor agonists for the treatment of Parkinson's disease is worthy of publication.</p> <p>I would like to make a few comments.</p> <p>1 The article does not discuss or consider the method of administration of GLP-1 receptor agonists. What are your thoughts on the relationship with oral semaglutide?</p> <p>2 In relation to #1, you mention that there are growth factors like GLP-1 that can pass through the BBB, but it has been reported that dulaglutide does not pass through the BBB at all. However, there are reports that dulaglutide also improves Parkinson's disease and cognitive function, and we should consider the possibility of a pathway or confounding factor other than the direct action of GLP-1.</p> <p>3 Although there are no comments on the concentration and dosage of GLP-1 receptor agonists in this study, we believe that this is an important point for future clinical use. Please give us your thoughts.</p> <p>We have drawn a yellow line through the commented part. Please refer to it. I would like to make a brief comment.</p>	

Review Form 1.7

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Yuki Nishiya
Department, University & Country	Hirosaki University of Medicine, Japan